Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 micro g/ethinyl estradiol 20 micro g.

Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington, VT 05401, USA.
Contraception (Impact Factor: 3.09). 02/2007; 75(1):23-6. DOI: 10.1016/j.contraception.2006.07.009
Source: PubMed

ABSTRACT The objective of this study was to evaluate the effect of a continuous daily regimen of levonorgestrel (LNG) 90 micro g/ethinyl estradiol (EE) 20 micro g on endometrial histology.
This was a substudy of a large phase 3 trial conducted in six sites in North America. Healthy and sexually active women aged between 18 and 49 years took LNG 90 micro g/EE 20 micro g daily for 1 year. Results from endometrial biopsies performed at pretreatment baseline and those after at least 6 months of treatment were compared.
Of the 146 participants, 93 had a baseline biopsy and completed at least six pill packs. Before treatment, 56 subjects (60%) had an endometrial biopsy with findings classified as "weakly proliferative or proliferative." During the last on-therapy visit, 48 subjects (52%) had an endometrium categorized as "other," which included primarily an inactive or benign endometrium (n=42). No hyperplasia or malignancy was observed during the study.
The results of a 1-year continuous regimen of LNG 90 micro g/EE 20 micro g were shown to have a good endometrial safety profile.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Many women have medical indications for menstrual suppression or a personal preference to reduce or eliminate monthly bleeding, which can be achieved with extended and continuous regimens of combined estrogen and progestin contraceptives. Combined contraceptives are traditionally administered in a 28-day cycle, with 21 days of a contraceptive pill, vaginal ring, or transdermal patch followed by a hormone-free interval that is usually 7 days. During the hormone-free interval, women either take a placebo pill or do not use their combined contraceptive method. Hormone-related symptoms are significantly worse during the hormone-free interval than the days when the contraceptive is used. Alterations of the standard 28-day cyclic regimen for menstrual suppression include decreasing the frequency of the hormone-free interval, thus extending the time between withdrawal bleeding episodes (extended use), and eliminating the hormone-free interval altogether (continuous use). This article reviews menstrual suppression indications and physiology. Research demonstrating that the effectiveness, safety, and side effects of oral, vaginal, and transdermal extended and continuous regimens are comparable to cyclic regimens is summarized. Findings from studies of women's and health care providers' attitudes toward menstrual suppression also are reviewed. Important topics to include in evidence-based counseling for extended and continuous combined contraceptive use are presented.
    Journal of midwifery & women's health 11/2012; 57(6):585-592. · 1.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Menstrual suppression, the use of contraceptive methods to eliminate or decrease the frequency of menses, is often prescribed for adolescents to treat menstrual disorders or to accommodate patient preference. For young women using hormonal contraceptives, there is no medical indication for menstruation to occur monthly, and various hormonal contraceptives can be used to decrease the frequency of menstruation with different side effect profiles and rates of amenorrhea. This article reviews the different modalities for menstrual suppression, common conditions in adolescents which may improve with menstrual suppression, and strategies for managing common side effects.
    Journal of pediatric and adolescent gynecology 11/2012; · 0.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Previous studies report association of contraceptives with moderate increase in urinary tract infection among sexually active premenopausal women. The aim of our study was to find out whether the use of hormonal contraceptives has any effect on microbiota of the vagina in the contraceptives users in Khairpur Sindh Pakistan. METHODS: A prospective study in woman population of Khairpur Sindh Pakistan aged 20--30 years and 31--40 years, using Hormonal contraceptives was carried out. High vaginal swab samples (n = 100) were collected from the test populations as well as control group (n = 100) and investigated for vaginal microbial flora using standard microbiological and biochemical techniques. RESULTS: Vaginal swabs culturing from hormonal contraceptives users in the age group 20--30 years showed statistically insignificant Candida sp (10 % samples), and statistically significant (p < 0.05) Staphylococcus saprophyticus. (18 % samples), Streptococcus agalactiae (23 % samples), Escherichia. coli (28 % samples) and Lactobacillus fermentum (32 % samples). In the age group 31--40 years, statistically significant percentage of samples (p < 0.05) showed Lactobacillus fermentum (28 %), Candida sp (24 %), and E. coli, (24 %) where statistically insignificant samples showed Staphylococcus saprophyticus (13 %) and Streptococcus agalactiae (11 %). CONCLUSIONS: The use of hormonal contraceptives alters the normal microbiota of vagina in women according to the age. Lactobacillus fermentum appeared as the predominant species followed by E. coli among the age group of 20--30 years and, Lactobacillus fermentum, Candida sp and E. coli as predominant among women of age group 31--40 years when compared to corresponding control groups. An inverse relationship between E. coli and Lactobacillus fermentum was observed in the women aged 20--30 years.
    BMC Urology 08/2012; 12(1):22. · 1.69 Impact Factor